Business
Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders
BRISBANE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company with a pipeline of targeted and immune-mediated therapeutics to fight cancer, today announced the record date of January 30, 2026 (the “Record Date”) for the distribution of warrants to purchase Tempest common stock (“Warrants”) as a dividend (the “Warrant Dividends”), as contemplated by Tempest’s previously announced Asset Purchase Agreement (the “Ass
About this update from Tempest Therapeutics, Inc.
[{"type":"image","alt":"Tempest Therapeutics","displaySize":"","headline":null,"caption":"Tempest Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":276,"url":"https://media.zenfs.com/en/globenewswire.com/2867b6171c53d10d1562509e04b23e18"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1LCUwp9cQJNg7WFUm2vLrg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM4NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2867b6171c53d10d1562509e04b23e18","width":300,"height":276}},"lazy":false},{"type":"text","content":"BRISBANE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company with a pipeline of targeted and immune-mediated therapeutics to fight cancer, today announced the record date of January 30, 2026 (the “Record Date”) for the distribution of warrants to purchase Tempest common stock (“Warrants”) as a dividend (the “Warrant Dividends”), as contemplated by Tempest’s previously announced Asset Purchase Agreement (the “Asset Purchase Agreement”) with Erigen LLC and Factor Bioscience Inc. The distribution of the Warrant Dividends is expected to be Tuesday, February 3, 2026, but is subject to the prior satisfaction of closing conditions for the transactions contemplated by the Asset Purchase Agreement (the “Closing Conditions”), including receipt of stockholder approval of Proposal 5 contained in Tempest’s definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on December 31, 2025 (“Stockholder Approval”).","length":1030,"tagName":"p"},{"type":"text","content":"The Warrants will be distributed by the Company’s warrant agent and will be exercisable following the distribution thereof, subject to the effectiveness of a registration statement registering the sale of the shares of common stock underlying the Warrants (the “Registration Statement”), in accordance with the terms of a warrant agreement.","length":340,"tagName":"p"},{"type":"text","content":"Warrant Terms","length":13,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Eligibility: Stockholders must hold shares at the close of business on January 30, 2026 in order to receive the Warrant Dividends.","length":130,"tagName":"p"}]},{"val":[{"type":"text","content":"Ratio: One (1) Warrant for every one (1) share of common st...